AI Article Synopsis
- There is a lack of evidence regarding the emetogenicity (the ability to cause vomiting) of intravenous pegaspargase in pediatric patients, which prevented its classification in clinical guidelines.
- A retrospective study reviewed records of 44 pediatric patients treated with IV pegaspargase from 2011 to 2020, focusing on those who did not vomit after treatment.
- The findings showed that all 13 patients who received anti-nausea medications had a complete response, leading to the recommendation of classifying IV pegaspargase as moderately emetogenic.
Article Abstract
Due to an evidence gap, the emetogenicity of intravenous (IV) pegaspargase was unable to be included in the clinical practice guideline classifying chemotherapy emetogenicity in pediatric patients. This single-center, retrospective chart review describes the proportion of pediatric patients who did not vomit during the acute phase (complete response; CR) after receiving IV pegaspargase and provides an emetogenicity classification using a preexisting framework. Of 44 patients who received IV pegaspargase between 2011 and 2020, 13 received a serotonin receptor antagonist plus dexamethasone or palonosetron alone and all experienced a CR. We, therefore, recommend classifying IV pegaspargase as moderately emetogenic.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/08880018.2024.2311886 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!